A sustainable business model based on innovation and ... - Roche
A sustainable business model based on innovation and ... - Roche
A sustainable business model based on innovation and ... - Roche
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
A well risk balanced approach to investment<br />
Most projects in late stage de-risked<br />
New<br />
Molecular<br />
Entities<br />
% of Pharma<br />
Development spend<br />
NMEs<br />
in<br />
Phase<br />
III<br />
40 NMEs in Phase I<br />
16 NMEs in Phase II<br />
dalcetrapib (CETPi)<br />
*PPARαγ<br />
taspoglutide (GLP-1)<br />
TDM-1<br />
ocrelizumab<br />
pertuzumab<br />
1 LE in Phase I<br />
Proof of C<strong>on</strong>cept<br />
<br />
<br />
<br />
<br />
<br />
Line<br />
Extensi<strong>on</strong>s<br />
42% 40%<br />
11 LEs in Phase II<br />
<br />
36 LEs in Phase III<br />
2007 2008<br />
* Formal decisi<strong>on</strong> to move into phase III pending<br />
10
Change language